Sponsor news UCB: make a real impact in the global response to the pandemic
As a global biopharma leader, Belgium based UCB is contributing actively to combat COVID-19.
UCB is helping there where it can make a real impact for patients, people, and society. None of this can be achieved without ensuring the safety of its 7,500 employees. Another key priority is to make sure that patients get access to the medicines regardless of the logistical challenges COVID-19 is bringing. By embracing new digital technology, UCB China and JD jointly launched a “Epilepsy Care Center” on JD.com to help epileptic patients and their caregivers better manage this chronic disease remotely.
To back our communities, we are contributing to basic research and treatment development in collaboration with various researchers and governments, offering its expertise to increase local testing capabilities in countries where UCB has the required facilities, supporting locally and globally through donations as well as direct assistance to patients and partners. The company donated protective materials to healthcare organizations in China, the United States and Belgium; as there are healthcare professionals amongst their employees, they are supporting them if they wish to volunteer their expertise to local governments in the fight against COVID-19. Just to name a few.
Beyond all the great work that is being done, UCB announced in early May the creation of a global fund to support researchers and organizations committed to better understanding and addressing the medium-and-long term impact of COVID-19 on vulnerable populations’ health.
An original article from UCB http://www.ucb.com/